Diabetes mellitus type 2

Active Ingredient: Lixisenatide

Indication for Lixisenatide

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Lixisenatide is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together, with diet and exercise, do not provide adequate glycaemic control

For this indication, competent medicine agencies globally authorize below treatments:

10 ug once daily for 14 days and thereafter 20 ug once daily

For:

Dosage regimens

Subcutaneous, 10 micrograms lixisenatide, once daily -60 minutes before meals, over the duration of 14 days. Afterwards, subcutaneous, 20 micrograms lixisenatide, once daily -60 minutes before meals, over the duration of 14 days.

Detailed description

Starting dose: dosing is initiated at 10 mcg lixisenatide once daily for 14 days.

Maintenance dose: a fixed maintenance dose of 20 mcg lixisenatide once daily is started on Day 15.

When lixisenatide is added to existing metformin therapy, the current metformin dose can be continued unchanged.

When lixisenatide is added to existing therapy of a sulphonylurea or a basal insulin, a reduction in the dose of the sulphonylurea or the basal insulin may be considered to reduce the risk of hypoglycaemia.

Lixisenatide should not be given in combination with basal insulin and a sulphonylurea due to increased risk of hypoglycaemia.

The use of lixisenatide does not require specific blood glucose monitoring. However, when used in combination with a sulphonylurea or a basal insulin, blood glucose monitoring or blood glucose self-monitoring may become necessary to adjust the doses of the sulphonylurea or the basal insulin.

Dosage considerations

Lixisenatide is to be injected subcutaneously in the thigh, abdomen or upper arm. Lixisenatide should not be administered intravenously or intramuscularly.

The injection is administered once daily, within the hour prior to any meal of the day. It is preferable that the prandial injection of lixisenatide is performed before the same meal every day, when the most convenient meal has been chosen. If a dose is missed, it should be injected within the hour prior to the next meal.

Active ingredient

Lixisenatide

Lixisenatide is a selective GLP-1 receptor agonist. The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from the pancreatic beta cells. Lixisenatide stimulates insulin secretion when blood glucose is increased but not at normoglycaemia, which limits the risk of hypoglycaemia. In parallel, glucagon secretion is suppressed. In case of hypoglycaemia, the rescue mechanism of glucagon secretion is preserved.

Read more about Lixisenatide

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.